Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GEN-1 + Pegylated liposomal doxorubicin |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GEN-1 | phIL-12-005|GEN1|GEN 1|IMNN-001|IMNN 001|IMNN001 | GEN-1 comprises a plasmid engineered to express IL-12 encapsulated within a lipopolymer, which potentially results in increased antitumor immune response (PMID: 28802766, PMID: 34326131). | ||
| Pegylated liposomal doxorubicin | Doxil | ATI-0918|CAELYX|liposomal doxorubicin | Chemotherapy - Anthracycline 13 | Doxil (pegylated liposomal doxorubicin) comprises the anthracyline doxorubicin, which intercalates into DNA and disrupts DNA replication, encapsulated in a liposome, which improves tumor penetration and decreases toxicity (NCI Drug Dictionary), and is FDA approved for ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|